What's Next For Bristol-Myers Squibb After Another Opdivo Setback?

Published: Aug 23, 2017

The signs were definitely there for a disappointment from Bristol-Myers Squibb. Several weeks ago, AstraZeneca reported its checkpoint inhibitor Imfinzi failed to improve progression-free survival in a late-stage study targeting lung cancer. There were concerns that Bristol-Myers Squibb (BMS) could experience a similar letdown when the company announced results from a late-stage study of its own checkpoint inhibitor, Opdivo, combined with chemotherapy in treating lung cancer.

A disappointment came, but it was in a totally different indication.

Back to news